|
In 2011, Embria received the Nutrition Business Journal |
In 2010, Embria received the SupplySide West |
|
In 2008, Embria received the Master Builders of Iowa |
In 2007, Embria received the Economic Impact Award |
|
In 2006, Embria received the Nutrition Business Journal Investment in the Future Award. |
In 2005, Embria received the Nutrition Business Journal Product Merit Award for eXselen. |
In 2011, Diamond V, Embria's parent company, received the Prometheus award for innovation and high-tech excellence including the establishment of Embria to bring its innovated technology to the human market.
In 2010, John Bloomhall, Diamond V's President and Ceo, received the Ernst & Young Entrepreneur of The Year Award Winner in the Central Midwest Region for building and leading dynamic, growing businesses including the establishment of Embria.
________________________________________________________________________________________
Proud Member of the Council for Responsible Nutrition (CRN)
A corporate member since 2006, Embria is active in several CRN committees and programs.
Appointed in 2013, Paul Faganel, Embria's President, serves as the supplier representative on the CRN Board. As a board member, Paul will serve in various leadership capacities, providing strategic direction, serving on Board committees and task forces, engaging in member mentorship activities, and more.
Kevin Boot, Embria's legal counsel, is currently a member of CRN's Regulatory Affairs Committee working to advance GMP compliance among manufacturers, and guiding the industry's Standardized Information on Dietary Ingredients initiative
Larry Robinson, Embria's Vice President of Scientific Affairs, is currently a member of the CRN's Senior Scientific Advisory Council.
________________________________________________________________________________________
Proud Member of the Iowa Biotech Association
The Iowa Biotech Association (IBA) was formed in 1994 to advance opportunities in Iowa for the improvement of the human environmental and economic well-being through the development and application of value added technologies in the life sciences.
